Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT05700058

Assessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults

Assessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults — Recruiting • Non-phase study • Diabetes / Metabolic • NCT05700058.

📅 01 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05700058
Start
2023-01-31
Completion
2026-09
ClinicaliQ Trial Snapshot
  • Assessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults — Recruiting • Non-phase study • Diabetes / Metabolic • NCT05700058.
  • One-sentence summary:.
  • This study tests three doses of leucine-enriched whey protein to find which best stimulates muscle building in older people.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Skeletal muscle accounts for approximately 45-55% of total body mass in healthy adults and plays a pivotal role in whole-body metabolic health, locomotion and physical independence. Undesirable loss of skeletal muscle mass (atrophy) is, however, a common feature of many diseases and scenarios including ageing, bed rest/immobilisation, cancer and physical inactivity. Despite the exact mechanisms causing muscle atrophy being not yet fully understood, "anabolic resistance" (reduced muscle building in response to protein feeding and exercise) is thought to be key, especially for age-related skeletal muscle losses (known as sarcopenia). As…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Why weight-loss jabs work better for some people than others
Diabetes / Metabolic · BBC Health · 10 Apr 2026
Genetic variations in appetite and digestion genes predict differential weight-loss responses to GLP-1 receptor agonists (Wegovy, Mounjaro), suggesting personalised medicine approaches may…
View brief →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Webinar
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
Diabetes / Metabolic · 0.5 · 05 Apr 2026
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline to review mechanism, evidence,…
Watch webinar →
Podcast
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
Diabetes / Metabolic · 00:15:32 · 03 Apr 2026
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide is a once-weekly GLP-1…
Listen →
Clinical Brief
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases
Diabetes / Metabolic · MHRA · 29 Jan 2026
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warni...
View brief →
Clinical Brief
GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation
Diabetes / Metabolic · MHRA · 28 Jan 2025
Healthcare professionals should be aware of the potential risk of pulmonary aspiration in patients using GLP-1 or dual GIP/GLP-1 receptor agonists who…
View brief →